Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

JAZZ – Jazz Pharmaceuticals plc

Float Short %

9.5

Margin Of Safety %

20

Put/Call OI Ratio

0.15

EPS Next Q Diff

14.8

EPS Last/This Y

-3.79

EPS This/Next Y

16.27

Price

123.21

Target Price

183.25

Analyst Recom

1.2

Performance Q

14.19

Relative Volume

0.97

Beta

0.23

Ticker: JAZZ




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25JAZZ118.280.110.7110168
2025-07-28JAZZ117.420.110.6110170
2025-07-29JAZZ116.580.120.0210241
2025-07-30JAZZ116.120.110.3810547
2025-07-31JAZZ114.640.110.9610631
2025-08-01JAZZ115.560.120.0110668
2025-08-04JAZZ116.170.114.7711464
2025-08-05JAZZ113.10.120.2311620
2025-08-06JAZZ106.010.140.0512932
2025-08-07JAZZ112.150.140.2613154
2025-08-08JAZZ111.740.140.2313180
2025-08-11JAZZ110.750.140.1013179
2025-08-12JAZZ113.290.150.7313120
2025-08-13JAZZ117.190.150.1213175
2025-08-14JAZZ116.670.150.0513148
2025-08-15JAZZ117.760.150.0713306
2025-08-18JAZZ117.720.160.0611280
2025-08-19JAZZ119.20.160.2411543
2025-08-20JAZZ1190.160.2911628
2025-08-21JAZZ120.570.160.0111674
2025-08-22JAZZ123.230.150.4611786
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25JAZZ118.23-217.9-371.14.83
2025-07-28JAZZ117.40-217.9-372.54.83
2025-07-29JAZZ116.60-217.9-372.44.83
2025-07-30JAZZ116.12-217.9-372.04.83
2025-07-31JAZZ114.63-217.9-373.44.83
2025-08-01JAZZ115.52-217.9-370.24.83
2025-08-04JAZZ116.10-217.9-370.74.83
2025-08-05JAZZ113.20-217.9-375.24.83
2025-08-06JAZZ106.01-217.9-381.14.83
2025-08-07JAZZ112.08-10.0-363.44.83
2025-08-08JAZZ111.30-10.0510.15.27
2025-08-11JAZZ110.81-9.9497.55.27
2025-08-12JAZZ113.37-9.9501.15.27
2025-08-13JAZZ117.12-9.9502.35.27
2025-08-14JAZZ116.59-9.9497.55.27
2025-08-15JAZZ117.74-9.9499.35.27
2025-08-18JAZZ117.68-9.9498.05.27
2025-08-19JAZZ119.20-9.9499.75.27
2025-08-20JAZZ119.02-9.9497.95.27
2025-08-21JAZZ120.55-9.9499.75.27
2025-08-22JAZZ123.21-9.9501.05.27
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25JAZZ2.58-0.359.91
2025-07-28JAZZ2.58-0.899.91
2025-07-29JAZZ2.58-0.899.91
2025-07-30JAZZ2.58-0.899.91
2025-07-31JAZZ2.58-0.899.91
2025-08-01JAZZ2.58-0.899.91
2025-08-04JAZZ2.58-0.569.91
2025-08-05JAZZ2.54-0.569.91
2025-08-06JAZZ2.60-0.569.91
2025-08-07JAZZ2.60-0.569.91
2025-08-08JAZZ2.60-0.569.91
2025-08-11JAZZ2.59-0.649.89
2025-08-12JAZZ2.59-0.649.47
2025-08-13JAZZ2.59-0.649.47
2025-08-14JAZZ2.59-0.649.47
2025-08-15JAZZ2.59-0.649.47
2025-08-18JAZZ2.56-2.319.50
2025-08-19JAZZ2.40-2.319.50
2025-08-20JAZZ2.40-2.319.50
2025-08-21JAZZ2.40-2.319.50
2025-08-22JAZZ2.40-2.319.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-9.07

Avg. EPS Est. Current Quarter

5.96

Avg. EPS Est. Next Quarter

5.73

Insider Transactions

2.4

Institutional Transactions

-2.31

Beta

0.23

Average Sales Estimate Current Quarter

1108

Average Sales Estimate Next Quarter

1161

Fair Value

147.92

Quality Score

48

Growth Score

68

Sentiment Score

96

Actual DrawDown %

34.8

Max Drawdown 5-Year %

-47.5

Target Price

183.25

P/E

Forward P/E

5.71

PEG

P/S

1.83

P/B

2.01

P/Free Cash Flow

5.9

EPS

-6.75

Average EPS Est. Cur. Y​

5.27

EPS Next Y. (Est.)

21.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.91

Relative Volume

0.97

Return on Equity vs Sector %

-35.6

Return on Equity vs Industry %

-22.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.49

EBIT Estimation

501
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading

Float Short %

9.5

Margin Of Safety %

20

Put/Call OI Ratio

0.15

EPS Next Q Diff

14.8

EPS Last/This Y

-3.79

EPS This/Next Y

16.27

Price

123.21

Target Price

183.25

Analyst Recom

1.2

Performance Q

14.19

Relative Volume

0.97

Beta

0.23

Ticker: JAZZ




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25JAZZ118.280.110.7110168
2025-07-28JAZZ117.420.110.6110170
2025-07-29JAZZ116.580.120.0210241
2025-07-30JAZZ116.120.110.3810547
2025-07-31JAZZ114.640.110.9610631
2025-08-01JAZZ115.560.120.0110668
2025-08-04JAZZ116.170.114.7711464
2025-08-05JAZZ113.10.120.2311620
2025-08-06JAZZ106.010.140.0512932
2025-08-07JAZZ112.150.140.2613154
2025-08-08JAZZ111.740.140.2313180
2025-08-11JAZZ110.750.140.1013179
2025-08-12JAZZ113.290.150.7313120
2025-08-13JAZZ117.190.150.1213175
2025-08-14JAZZ116.670.150.0513148
2025-08-15JAZZ117.760.150.0713306
2025-08-18JAZZ117.720.160.0611280
2025-08-19JAZZ119.20.160.2411543
2025-08-20JAZZ1190.160.2911628
2025-08-21JAZZ120.570.160.0111674
2025-08-22JAZZ123.230.150.4611786
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25JAZZ118.23-217.9-371.14.83
2025-07-28JAZZ117.40-217.9-372.54.83
2025-07-29JAZZ116.60-217.9-372.44.83
2025-07-30JAZZ116.12-217.9-372.04.83
2025-07-31JAZZ114.63-217.9-373.44.83
2025-08-01JAZZ115.52-217.9-370.24.83
2025-08-04JAZZ116.10-217.9-370.74.83
2025-08-05JAZZ113.20-217.9-375.24.83
2025-08-06JAZZ106.01-217.9-381.14.83
2025-08-07JAZZ112.08-10.0-363.44.83
2025-08-08JAZZ111.30-10.0510.15.27
2025-08-11JAZZ110.81-9.9497.55.27
2025-08-12JAZZ113.37-9.9501.15.27
2025-08-13JAZZ117.12-9.9502.35.27
2025-08-14JAZZ116.59-9.9497.55.27
2025-08-15JAZZ117.74-9.9499.35.27
2025-08-18JAZZ117.68-9.9498.05.27
2025-08-19JAZZ119.20-9.9499.75.27
2025-08-20JAZZ119.02-9.9497.95.27
2025-08-21JAZZ120.55-9.9499.75.27
2025-08-22JAZZ123.21-9.9501.05.27
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25JAZZ2.58-0.359.91
2025-07-28JAZZ2.58-0.899.91
2025-07-29JAZZ2.58-0.899.91
2025-07-30JAZZ2.58-0.899.91
2025-07-31JAZZ2.58-0.899.91
2025-08-01JAZZ2.58-0.899.91
2025-08-04JAZZ2.58-0.569.91
2025-08-05JAZZ2.54-0.569.91
2025-08-06JAZZ2.60-0.569.91
2025-08-07JAZZ2.60-0.569.91
2025-08-08JAZZ2.60-0.569.91
2025-08-11JAZZ2.59-0.649.89
2025-08-12JAZZ2.59-0.649.47
2025-08-13JAZZ2.59-0.649.47
2025-08-14JAZZ2.59-0.649.47
2025-08-15JAZZ2.59-0.649.47
2025-08-18JAZZ2.56-2.319.50
2025-08-19JAZZ2.40-2.319.50
2025-08-20JAZZ2.40-2.319.50
2025-08-21JAZZ2.40-2.319.50
2025-08-22JAZZ2.40-2.319.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-9.07

Avg. EPS Est. Current Quarter

5.96

Avg. EPS Est. Next Quarter

5.73

Insider Transactions

2.4

Institutional Transactions

-2.31

Beta

0.23

Average Sales Estimate Current Quarter

1108

Average Sales Estimate Next Quarter

1161

Fair Value

147.92

Quality Score

48

Growth Score

68

Sentiment Score

96

Actual DrawDown %

34.8

Max Drawdown 5-Year %

-47.5

Target Price

183.25

P/E

Forward P/E

5.71

PEG

P/S

1.83

P/B

2.01

P/Free Cash Flow

5.9

EPS

-6.75

Average EPS Est. Cur. Y​

5.27

EPS Next Y. (Est.)

21.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.91

Relative Volume

0.97

Return on Equity vs Sector %

-35.6

Return on Equity vs Industry %

-22.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.49

EBIT Estimation

501
Jazz Pharmaceuticals plc
Sector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading